Pfizer Inc. (NYSE:PFE) Shares Purchased by Rock Creek Group LP

Rock Creek Group LP raised its position in Pfizer Inc. (NYSE:PFE) by 26.7% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 10,791 shares of the biopharmaceutical company’s stock after buying an additional 2,272 shares during the quarter. Rock Creek Group LP’s holdings in Pfizer were worth $423,000 as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. Benjamin Edwards Inc. raised its stake in shares of Pfizer by 36.5% during the 1st quarter. Benjamin Edwards Inc. now owns 999 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 267 shares in the last quarter. Alpha DNA Investment Management LLC raised its position in Pfizer by 52.2% in the first quarter. Alpha DNA Investment Management LLC now owns 1,090 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 374 shares in the last quarter. Lake Point Wealth Management acquired a new stake in Pfizer in the second quarter valued at $49,000. Abundance Wealth Counselors acquired a new position in shares of Pfizer during the 1st quarter worth $51,000. Finally, KB Financial Partners LLC purchased a new position in shares of Pfizer in the 1st quarter valued at about $62,000. Institutional investors own 64.93% of the company’s stock.

Several research analysts have weighed in on PFE shares. Morgan Stanley upped their target price on shares of Pfizer from $42.00 to $45.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 29th. Truist began coverage on Pfizer in a report on Tuesday, July 27th. They set a “buy” rating and a $43.00 price objective for the company. The Goldman Sachs Group set a $48.00 target price on Pfizer in a report on Thursday, July 29th. SVB Leerink reaffirmed a “hold” rating and set a $49.00 price target on shares of Pfizer in a research note on Tuesday. Finally, JPMorgan Chase & Co. increased their price objective on shares of Pfizer from $40.00 to $42.00 and gave the company a “neutral” rating in a research note on Monday. Eleven equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus price target of $42.77.

In other news, SVP Jennifer B. Damico sold 2,500 shares of the firm’s stock in a transaction on Friday, July 30th. The shares were sold at an average price of $42.86, for a total value of $107,150.00. Following the transaction, the senior vice president now owns 11,430 shares of the company’s stock, valued at approximately $489,889.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Jennifer B. Damico sold 1,661 shares of the company’s stock in a transaction on Friday, August 13th. The stock was sold at an average price of $48.30, for a total transaction of $80,226.30. The disclosure for this sale can be found here. 0.05% of the stock is owned by insiders.

PFE stock opened at $44.71 on Wednesday. The stock has a market capitalization of $250.68 billion, a price-to-earnings ratio of 19.19, a price-to-earnings-growth ratio of 1.58 and a beta of 0.74. The stock’s fifty day simple moving average is $44.74 and its 200-day simple moving average is $40.35. Pfizer Inc. has a 52-week low of $33.36 and a 52-week high of $51.86. The company has a quick ratio of 1.12, a current ratio of 1.37 and a debt-to-equity ratio of 0.50.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Wednesday, July 28th. The biopharmaceutical company reported $1.07 EPS for the quarter, beating the consensus estimate of $0.97 by $0.10. The company had revenue of $18.98 billion during the quarter, compared to analysts’ expectations of $17.54 billion. Pfizer had a return on equity of 26.49% and a net margin of 23.06%. During the same quarter in the previous year, the business earned $0.78 EPS. As a group, analysts anticipate that Pfizer Inc. will post 4.12 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 7th. Shareholders of record on Friday, July 30th were issued a $0.39 dividend. The ex-dividend date was Thursday, July 29th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.49%. Pfizer’s dividend payout ratio (DPR) is presently 70.27%.

Pfizer Profile

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Recommended Story: How do investors use RSI to grade stocks?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.